Annual report
4564.TEDINET S100W4BQ
Period2024-04-01 → 2025-03-31
Filed2025-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 124
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥750m | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥610m | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | −¥798m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥813m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | −¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥3.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥514m | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.1bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥528m | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥795m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥52m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥96m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.86 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4.04 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥16.96 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 47 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 54 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 60 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 67 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 66 | at 2021-03-31d | Cons. | Number of employees |
| Operating income | −¥728m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | −¥889m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | −¥712m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥873m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥814m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥840m | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥507m | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥949m | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.9bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111m | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥154m | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥729m | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥575m | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥614m | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥325m | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.8 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-8.77 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.58 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥14.53 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 78.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 271,643,700 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 217,643,700 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,332,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 18 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 27 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 36 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 35 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥107m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥220m |
| Cancer Precision Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| Cancer Precision Medical Businessreportable segment | employees | at 2025-03-31 | 29 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥470m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥91m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2025-03-31 | 18 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2025-03-31 | ¥792m |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥487m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| —segment total | segment assets | at 2025-03-31 | ¥1.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | −¥578m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥270,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥270,000 |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥211m |
| Cancer Precision Medical Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥155m |
| Cancer Precision Medical Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥610m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥610m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2024-03-31 | ¥407m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥236m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥698,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥427,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥270,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2024-03-31 | ¥459m |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥675m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥155m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥610m |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥610m |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥270,000 |
| —segment total | segment assets | at 2024-03-31 | ¥866m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | −¥910m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2025-03-31 | 18 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,168
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net fin cf | Prior1YearDuration | -2000 | JPY |
| Other net fin cf | CurrentYearDuration | -1000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | 671365000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 1121527000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -589978000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 306227000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1117635000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 527656000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 527656000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 833883000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 1 | |
| Outsourcing expenses research and development expenses | Prior1YearDuration | 382980000 | JPY |
| Outsourcing expenses research and development expenses | CurrentYearDuration | 236163000 | JPY |
| Payrolls and allowances research and development expenses | Prior1YearDuration | 117776000 | JPY |
| Payrolls and allowances research and development expenses | CurrentYearDuration | 101796000 | JPY |
| Patent costs research and development expenses | Prior1YearDuration | 101814000 | JPY |
| Patent costs research and development expenses | CurrentYearDuration | 86435000 | JPY |
| Commission fee sga | Prior1YearDuration | 89634000 | JPY |
| Commission fee sga | CurrentYearDuration | 111118000 | JPY |
| Directors compensations sga | Prior1YearDuration | 56500000 | JPY |
| Directors compensations sga | CurrentYearDuration | 57620000 | JPY |
| Payroll and allowances sga | Prior1YearDuration | 56361000 | JPY |
| Payroll and allowances sga | CurrentYearDuration | 55030000 | JPY |
| Taxes and dues sga | Prior1YearDuration | 4350000 | JPY |
| Taxes and dues sga | CurrentYearDuration | 5852000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 427000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 609690000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 610118000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 610118000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 270000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 270000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -270000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 698000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 609690000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 610388000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -270000 | JPY |
| Net sales | Prior1YearDuration | 610118000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | -674559000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | -235633000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | -910192000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -210607000 | JPY |
| Operating income | Prior1YearDuration | -1120800000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember | 458814000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember | 406945000 | JPY |
| Assets | Prior1YearInstant_ReportableSegmentsMember | 865759000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 1515000 | JPY |
| Assets | Prior1YearInstant | 867275000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |